Autologous stem cell therapy for hypoplastic left heart syndrome: Safety and feasibility of intraoperative intramyocardial injections.

Published on Dec 1, 2019in The Journal of Thoracic and Cardiovascular Surgery4.451
· DOI :10.1016/J.JTCVS.2019.06.001
Harold M. Burkhart53
Estimated H-index: 53
(OU: University of Oklahoma),
Muhammad Yasir Qureshi10
Estimated H-index: 10
(Mayo Clinic)
+ 32 AuthorsJoan Wobig1
Estimated H-index: 1
Sources
Abstract
Abstract Objectives Staged surgical palliation for hypoplastic left heart syndrome results in an increased workload on the right ventricle serving as the systemic ventricle. Concerns for cardiac dysfunction and long-term heart failure have generated interest in first-in-infant, cell-based therapies as an additional surgical treatment modality. Methods A phase 1 clinical trial was conducted to evaluate the safety and feasibility of direct intramyocardial injection of autologous umbilical cord blood-derived mononuclear cells in 10 infants with hypoplastic left heart syndrome at the time of stage II palliation. Results All 10 patients underwent successful stage II palliation and intramyocardial injection of umbilical cord blood-derived mononuclear cells. Operative mortality was 0%. There was a single adverse event related to cell delivery: An injection site epicardial bleed that required simple oversew. The cohort did not demonstrate any significant safety concerns over 6 months. Additionally, the treatment group did not demonstrate any reduction in cardiac function in the context of the study related intramyocardial injections of autologous cells. Conclusions This phase 1 clinical trial showed that delivering autologous umbilical cord blood-derived mononuclear cells directly into the right ventricular myocardium during planned stage II surgical palliation for hypoplastic left heart syndrome was safe and feasible. Secondary findings of preservation of baseline right ventricular function throughout follow-up and normalized growth rates support the design of a phase 2b follow-up trial.
📖 Papers frequently viewed together
80 Citations
78 Citations
48 Citations
References25
Newest
#1Anastacia M. Garcia (University of Colorado Denver)H-Index: 7
#2Jonathan-Thomas Beatty (University of Colorado Denver)H-Index: 2
Last. Stephanie J. Nakano (University of Colorado Denver)H-Index: 8
view all 3 authors...
Due to remarkable surgical and medical advances over the past several decades, there are growing numbers of infants and children living with single ventricle congenital heart disease (SV), where th...
11 CitationsSource
#1Gregory J. BittleH-Index: 12
#2David L.S. MoralesH-Index: 54
Last. Sunjay KaushalH-Index: 20
view all 14 authors...
Hypoplastic left heart syndrome is a type of congenital heart disease characterized by underdevelopment of the left ventricle, outflow tract, and aorta. The condition is fatal if aggressive palliative operations are not undertaken, but even after the complete 3-staged surgical palliation, there is significant morbidity because of progressive and ultimately intractable right ventricular failure. For this reason, there is interest in developing novel therapies for the management of right ventricul...
22 CitationsSource
#1Jorge Bartolucci (University of the Andes, Chile)H-Index: 5
#2Fernando J. Verdugo (University of the Andes, Chile)H-Index: 2
Last. Maroun Khoury (University of the Andes, Chile)H-Index: 29
view all 19 authors...
Rationale: Umbilical cord-derived mesenchymal stem cells (UC-MSC) are easily accessible and expanded in vitro, possess distinct properties, and improve myocardial remodeling and function in experimental models of cardiovascular disease. While bone marrow-derived mesenchymal stem cells (BM-MSCs) have been previously assessed for their therapeutic potential in individuals with heart failure and reduced ejection fraction (HFrEF), no clinical trial has evaluated UC-MSCs in these patients. Objective:...
161 CitationsSource
#1Sunjay Kaushal (UMB: University of Maryland, Baltimore)H-Index: 20
#2Brody Wehman (UMB: University of Maryland, Baltimore)H-Index: 14
Last. Joshua M. Hare (UM: University of Miami)H-Index: 109
view all 18 authors...
Despite advances in surgical technique and postoperative care, long-term survival of children born with hypoplastic left heart syndrome (HLHS) remains limited, with cardiac transplantation as the only alternative for patients with failing single ventricle circulations. Maintenance of systemic right ventricular function is crucial for long-term survival, and interventions that improve ventricular function and avoid or defer transplantation in patients with HLHS are urgently needed. We hypothesize...
24 CitationsSource
#1Joshua M. Hare (UM: University of Miami)H-Index: 109
#2Darcy L. DiFede (UM: University of Miami)H-Index: 17
Last. Alan W. Heldman (UM: University of Miami)H-Index: 37
view all 32 authors...
Abstract Background Although human mesenchymal stem cells (hMSCs) have been tested in ischemic cardiomyopathy, few studies exist in chronic nonischemic dilated cardiomyopathy (NIDCM). Objectives The authors conducted a randomized comparison of safety and efficacy of autologous (auto) versus allogeneic (allo) bone marrow-derived hMSCs in NIDCM. Methods Thirty-seven patients were randomized to either allo- or auto-hMSCs in a 1:1 ratio. Patients were recruited between December 2011 and July 2015 at...
174 CitationsSource
#1Christian P. Brizard (University of Melbourne)H-Index: 47
#2Jeffrey Y.J. Looi (University of Melbourne)H-Index: 1
Last. Salvatore Pepe (University of Melbourne)H-Index: 39
view all 7 authors...
Background One potential approach for advancing univentricular heart surgical palliation outcomes is by stem cell therapy to augment right ventricular function and muscle mass. Whether the stem cell–inclusive cord blood mononuclear cells (CBMNCs) are safe to perfuse into the coronary vasculature during neonatal cardiopulmonary bypass (CPB) is unknown. We evaluated the acute safety, functional effects, and fate of human CBMNCs in a novel model of coronary vasculature delivery in a lamb model of i...
5 CitationsSource
#1Saji Oommen (Mayo Clinic)H-Index: 16
#2Satsuki Yamada (Mayo Clinic)H-Index: 23
Last. Timothy J. NelsonH-Index: 38
view all 7 authors...
Introduction Stem cell therapy has emerged as potential therapeutic strategy for damaged heart muscles. Umbilical cord blood (UCB) cells are the most prevalent stem cell source available, yet have not been fully tested in cardiac regeneration. Herein, studies were performed to evaluate the cardiovascular safety and beneficial effect of mononuclear cells (MNCs) isolated from human umbilical cord blood upon intramyocardial delivery in a murine model of right ventricle (RV) heart failure due to pre...
22 CitationsSource
#1Harold M. Burkhart (Mayo Clinic)H-Index: 53
#2Muhammad Yasir Qureshi (Mayo Clinic)H-Index: 10
Last. Timothy J. NelsonH-Index: 38
view all 7 authors...
The current standard of care for neonates with hypoplastic left heart syndrome (HLHS) includes a series of cardiac operations culminating in a complete cavopulmonary connection. Given the increased workload placed on the right ventricle, development of ventricular dysfunction and heart failure are concerns. As this patient population ages, many may require cardiac transplantation. Cellbased strategies to treat heart failure in adults have been reported, but little is known about their feasibilit...
48 CitationsSource
#1Shuta Ishigami (Okayama University)H-Index: 4
#2Shinichi Ohtsuki (Okayama University)H-Index: 10
Last. Hidemasa Oh (Okayama University)H-Index: 21
view all 19 authors...
Rationale: Hypoplastic left heart syndrome (HLHS) remains a lethal congenital cardiac defect. Recent studies have suggested that intracoronary administration of autologous cardiosphere-derived cells (CDCs) may improve ventricular function. Objective: The aim of this study was to test whether intracoronary delivery of CDCs is feasible and safe in patients with HLHS. Methods and Results: Between January 5, 2011, and January 16, 2012, 14 patients (1.8 ± 1.5 years) were prospectively assigned to rec...
119 CitationsSource
#1Susana Cantero Peral (Autonomous University of Barcelona)H-Index: 5
#2Harold M. BurkhartH-Index: 53
Last. Timothy J. NelsonH-Index: 38
view all 10 authors...
Congenital heart diseases (CHDs) requiring surgical palliation mandate new treatment strategies to optimize long-term outcomes. Despite the mounting evidence of cardiac regeneration, there are no long-term safety studies of autologous cell-based transplantation in the pediatric setting. We aimed toestablishaporcinepipelinetoevaluatethefeasibilityandlong-termsafetyofautologousumbilical cord blood mononuclear cells (UCB-MNCs) transplanted into the right ventricle (RV) of juvenile porcine hearts. P...
19 CitationsSource
Cited By21
Newest
#1Patrick W. O'Leary (Mayo Clinic)H-Index: 40
#2M. Yasir Qureshi (Mayo Clinic)H-Index: 5
Last. Angela R. MillerH-Index: 2
view all 15 authors...
Abstract null null Objective null To define the impact of tricuspid valve cone reconstruction (CR) on ventricular performance in Ebstein anomaly, both independently and after stem cell therapy. null null null Patients and Methods null The control group included 257 patients who had CR between June 2007 and December 2019. Ten subjects of a phase I stem cell therapy trial (May 2017 – March 2019) were compared with the controls to assess the echocardiographic impact on ventricular remodeling. null ...
Source
#3Yves d'UdekemH-Index: 45
Abstract Pediatric heart surgery is still a young discipline. The first operations to treat congenital heart diseases were done in the early 1940s and its real expansion ensued after intra-cardiac procedures were feasible with acceptable risk following wider access to the use of cardio-pulmonary bypass machine. The first two decades of existence of this specialty saw a whirlwind of new procedures making it one of the most quickly evolving specialty. Pioneers tested and abandoned operations by ra...
1 CitationsSource
#1Filippo RapettoH-Index: 7
#2Demetris TaliotisH-Index: 4
Last. Massimo CaputoH-Index: 40
view all 10 authors...
Abstract Cell therapy is a promising tool to prevent and treat heart failure in congenital heart disease. We report the first case of intramyocardial injection of allogeneic mesenchymal stromal cells as rescue therapy in a neonate with ischemic heart failure following arterial switch procedure for isolated transposition of the great arteries. (Level of Difficulty: Advanced.)
Source
#1Cuican Li (CPU: China Pharmaceutical University)H-Index: 3
#2Muhammad Naveed (CPU: China Pharmaceutical University)H-Index: 55
Last. Zhou Xiaohui (SEU: Southeast University)H-Index: 6
view all 10 authors...
The most commonly used administration methods in clinics and life are oral administration, intravenous injection, and other systemic administration methods. Targeted administration must be an essen...
1 CitationsSource
#2Joseph A. Dearani (UR: University of Rochester)H-Index: 95
#5Bryan C. Cannon (UR: University of Rochester)H-Index: 29
Last. Karen Cavanaugh (Mayo Clinic)H-Index: 2
view all 13 authors...
Abstract Background The objective of this study is to assess the safety and early impact of intramyocardial delivery of autologous bone marrow-derived mononuclear cells (BM-MNC) at time of surgical Ebstein repair. Methods Patients with EA (ages 6 months to 30 years) scheduled to undergo repair of the TV were eligible to participate in this open label, non-randomized Phase I clinical trial. BM-MNC target dose was 1-3 million cells/kg. Ten patients have undergone surgical intervention and cell del...
2 CitationsSource
#1Margaret Rose Ferrari (Anschutz Medical Campus)
#2Michael V. Di Maria (Anschutz Medical Campus)H-Index: 11
Last. Jeffrey G. Jacot (Anschutz Medical Campus)H-Index: 19
view all 3 authors...
Though the current staged surgical strategy for palliation of single ventricle heart disease, culminating in a Fontan circulation, has increased short-term survival, mounting evidence has shown that the single ventricle, especially a morphologic right ventricle (RV), is inadequate for long-term circulatory support. In addition to high rates of ventricular failure, high central venous pressures (CVP) lead to liver fibrosis or cirrhosis, lymphatic dysfunction, kidney failure, and other comorbiditi...
Source
Hypoplastic left heart syndrome is a constellation of malformations which result from the severe underdevelopment of any left-sided cardiac structures. Once considered to be universally fatal, the prognosis for this condition has tremendously improved over the past four decades since the work of William Norwood in the early 1980s. Today, a staged surgical approach is applied for palliating this distinctive cohort of patients, in which they undergo three operative procedures in the first 10 years...
Source
Current surgical and medical treatment options for single ventricle physiology conditions remain palliative. On the long term, despite treatment, the systemic ventricle has a significant risk of developing failure. There are unmet needs to develop novel treatment modalities to help ameliorate the ventricular dysfunction. Advances in the field of stem cell therapy have been promising for the treatment of heart failure. Numerous stem cell populations have been identified. Preclinical studies in sm...
Source
#1Christoph Haller (U of T: University of Toronto)H-Index: 6
#2Mark K. Friedberg (U of T: University of Toronto)H-Index: 42
Last. Michael A. Laflamme (U of T: University of Toronto)H-Index: 33
view all 3 authors...
Right ventricular (RV) failure is a commonly encountered problem in patients with congenital heart disease but can also be a consequence of left ventricular disease, primary pulmonary hypertension, or RV-specific cardiomyopathies. Improved survival of the aforementioned pathologies has led to increasing numbers of patients suffering from RV dysfunction, making it a key contributor to morbidity and mortality in this population. Currently available therapies for heart failure were developed for th...
5 CitationsSource
#1Mehdi Hassanpour (Tabriz University of Medical Sciences)H-Index: 9
Last. Mohammad NouriH-Index: 26
view all 5 authors...
Cardiovascular diseases (CVDs) are the leading cause of death globally. Because of the economic and social burden of acute myocardial infarction and its chronic consequences in surviving patients, understanding the pathophysiology of myocardial infarction injury is a major priority for cardiovascular research. MI is defined as cardiomyocytes death caused by an ischemic that resulted from the apoptosis, necrosis, necroptosis, and autophagy. The phases of normal repair following MI including infla...
Source